- Drugs List
- Therapeutic Indications
- Precautions and Warnings
- Pregnancy and Lactation
- Side Effects
Injections of fulvestrant.
Hormone receptor +ve, HER2 -ve locally advanced or metastatic breast cancer
Hormone-dependent metastatic breast cancer in postmenopausal patients
Oestrogen receptor positive, locally advanced or metastatic breast cancer in post menopausal women not treated previously with endocrine treatment.
Oestrogen receptor positive, locally advanced or metastatic breast cancer in post menopausal women where disease has relapsed during or after anti-oestrogen treatment or disease progression while on anti-oestrogen treatment.
Adjunctive treatment with palbociclib in hormone receptor positive, human epidermal growth factor receptor 2 negative, locally advanced or metastatic breast cancer in women who have received prior endocrine treatment.
When fulvestrant with palbociclib are given in combination in pre or peri-menopausal women, combine with luteinising hormone releasing hormone agonist.
Whilst the doses stated below are those recommended by the manufacturer, local cancer network protocols for the relevant indication should be consulted.
The recommended dose is 500mg fulvestrant at intervals of one month, with an additional 500mg dose given two weeks after the initial dose.
Two consecutive 5ml slow intramuscular injections (1-2 minutes/injection) one into each buttock.
Use caution if injecting at the dorsogluteal site due to the proximity of the underlying sciatic nerve.
Children under 18 years
Hypersensitivity to benzyl alcohol
Severe hepatic impairment
Precautions and Warnings
Predisposition to thromboembolic disease
History of alcohol abuse
Renal impairment - creatinine clearance below 30 ml/minute
Advise ability to drive/operate machinery may be affected by side effects
Contains benzyl alcohol
Caution injecting at dorsogluteal site due to proximity of sciatic nerve
Potential risk of osteoporosis
Female: Ensure adequate contraception during treatment
Caution should be used when treating patients with bleeding diatheses, thrombocytopenia or those taking concurrent anti-coagulants because of the route of administration (deep intramuscular injection into the buttock).
The efficacy and safety of fulvestrant in patients with critical visceral disease (as either monotherapy or in combination with palbociclib) has not been studied.
Pregnancy and Lactation
Fulvestrant is contraindicated during pregnancy.
The manufacturer recommends that fulvestrant is contraindicated during pregnancy. In animal studies, fulvestrant has been shown to cross the placenta and has shown reproductive toxicity, including an increased incidence of foetal abnormalities and death. If pregnancy occurs during treatment, the patient must be informed of the potential hazard to the foetus and the potential risk for loss of pregnancy.
Fulvestrant is contraindicated during breastfeeding.
The manufacturer reccomends that breastfeeding must be discontinued during treatment with fulvestrant. It is not known whether fulvestrant is excreted in human breast milk but animal studies have shown that it is excreted into the milk of rats. Due to the potential for serious adverse reactions in a nursing infant, fulvestrant is contraindicated while breastfeeding.
Gamma glutamyl transferase (GGT) increased
Haematoma (injection site)
Haemorrhage (injection site)
Increase in alkaline phosphatase
Increase in serum ALT/AST
Injection site reactions
Reduced platelet count
Serum bilirubin increased
Urinary tract infections
Effects on Laboratory Tests
Fulvestrant may cause falsely elevated estradiol results in assays. The similar chemical structure to estradiol means it may cross-react with the antibodies used in immunoassays.
It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management.
The following number will direct the caller to the relevant local centre (0844) 892 0111
Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet ( www.toxbase.org ) or if this is unavailable at the backup site ( www.toxbasebackup.org ).
Last Full Review Date: February 2021
Joint Formulary Committee. British National Formulary (online) London: BMJ Group and Pharmaceutical Press. Accessed on 9 February 2021.
Summary of Product Characteristics: Faslodex 250 mg solution for injection. AstraZeneca UK Limited. Revised April 2020.
Summary of Product Characteristics: Fulvestrant Dr. Reddy's 250mg Solution for Injection in Pre-Filled Syringe. Dr. Reddy's Laboratories (UK) Ltd. Revised March 2020.
Summary of Product Characteristics: Fulvestrant Teva 250mg Solution for Injection in Pre-Filled Syringe. Teva UK Limited. Revised April 2018.
Already a member? Log in
Medscape UK | Univadis prescription drug monographs & interactions are based on FDB Multilex Content
FDB Disclaimer : FDB Multilex is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.